Answers are grounded in this paper and cite their sources.
Case report demonstrates left ventricular dysfunction following lacosamide administration in a preterm neonate, highlighting potential risks of sodium channel blockers in vulnerable infants.
Lacosamide (Vimpat Harris FRC Corporation, 2022 UCB, Inc. Smyrna, GA 30080) is an antiseizure medication, which acts through blockage of voltage-gated neuronal sodium channels. Its recent implementation in the neonatal population has been extrapolated from adult and pediatric data suggesting a favorable safety profile. Of note, preterm infants have unique developmental characteristics that may predispose them to increased risk of adverse reactions. We present a case of a preterm neonate who developed left ventricular dysfunction coinciding with the initiation of lacosamide.
No takes yet. Share an insight, caveat, or question.
Chatmethakul et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: